Novel Technologies News for July 2012

Novel Technologies News Archive

Vanderbilt-led team to develop ‘Microbrain’ to improve drug testing Vanderbilt-led team to develop ‘Microbrain’ to improve drug testing

An interdisciplinary team of researchers from Vanderbilt University, Vanderbilt University Medical Center, the Cleveland Clinic and Meharry Medical College are creating a "microbrain bioreactor” to monitor how the human brain responds when exposed to minute quantities of dietary toxins, disease organisms or new drugs under development.

Tailor-made treatments in oncology to dominate future therapy Tailor-made treatments in oncology to dominate future therapy

Cancer treatments are becoming increasingly personalized, as regulators are approving therapeutics offering significant benefits to small target populations, according to a new report by healthcare experts GBI Research.

Cancer Research Technology and ADC Therapeutics join forces on antibody drug conjugates Cancer Research Technology and ADC Therapeutics join forces on antibody drug conjugates

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announced that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.

In silico therapy for schizophrenia? In silico therapy for schizophrenia?

Brain Plasticity, Inc. (BPI) of California is spearheading the Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (e-CAeSAR) clinical trial in collaboration with the National Institute of Mental Health (NIMH) to evaluate a computer-based brain-plasticity program.